Pharmacogenomics

In this month's "Hot Topic," Paul Jannetto, Ph.D., identifies how to determine new vs. residual use of marijuana in a patient, and teaches how to calculate the carboxy-tetrahydrocannabinol (carboxy-THC) to creatinine ratio along with a decision ratio by demonstrating its clinical utility via case study.

By MCL Education • March 7, 2022

PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” Victor Karpyak, M.D., Ph.D., discusses the burden of alcohol use disorders (AUD) on society compared to other neuropsychiatric disorders and reviews the progress of biomarker discovery.

By MCL Education • December 16, 2021

Pharmacogenomic testing is still limited, despite ample research, the existence of guidelines, and the emerging evidence it can help patients. Ann Moyer, M.D., Ph.D., Co-Director of the Personalized Genomics Laboratory at Mayo Clinic in Rochester, Minnesota, makes a case for pharmacogenomics.

By Kelley Luedke • July 2, 2018

Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.

By Mayo Clinic Laboratories • October 25, 2017

Insights gained from algorithms should be shared with clinicians as a way to improve patient care, increase efficiency, and reduce costs.

By Brent Westra • July 1, 2017

The algorithm can be viewed here.

By Brent Westra • July 1, 2017

Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.

By Mayo Clinic Laboratories • March 29, 2017